If you missed this week's episode of Cases with Castle featuring Dr. Witkowski, don't worry - you can catch the replay here: https://hubs.la/Q02DB2Lb0. #caseswithcastle #genetictesting #melanoma Castle Biosciences, Inc.
MyPath Melanoma
Medical and Diagnostic Laboratories
Friendswood, Texas 546 followers
Objective information to aid in the diagnosis and inform management for patients with ambiguous melanocytic lesions.
About us
Diagnostic GEP testing is intended to aid in the characterization of primary cutaneous lesions with uncertain malignant potential. Test results should be interpreted in the context of other clinical, laboratory, and histopathological findings.
- Website
-
https://castletestinfo.com/mypath-melanoma-diffdx-melanoma/
External link for MyPath Melanoma
- Industry
- Medical and Diagnostic Laboratories
- Company size
- 201-500 employees
- Headquarters
- Friendswood, Texas
Updates
-
Mark your calendar for a new Cases with Castle "GEP testing to achieve clinicopathological correlation in ambiguous melanocytic lesions" presented by Dr. Alexander Witkowski. Register today: https://lnkd.in/eVrzfGwY
-
-
MyPath Melanoma reposted this
Going to the Summer SDPA conference? Make sure to check out the Product Theater session on how to use GEP for personalized patient risk assessment.
This content isn’t available here
Access this content and more in the LinkedIn app
-
NEW MANUSCRIPT: The management of patient with melanocytic lesions is dependent on the diagnosis with guidelines defining treatment protocols for benign nevi and malignant melanomas. Even though diagnostic discordance and diagnostic ambiguity have been previously established, the real-world impact on patient management is not well understood. Using an exhaustive review process by multiple dermatopathologists and a simulated patient treatment model, this study reveals that diagnostic discordance and ambiguity may be more common that previously reported and identifies significant variation in patient treatment in these lesions. Read the full manuscript here: https://hubs.la/Q02yZtK00
-
-
NEW: Discover the latest case study from Castle Biosciences, Inc. showcasing the diagnosis and risk stratification of high-risk melanoma using MyPath Melanoma and DecisionDx-Melanoma. Read more: https://lnkd.in/eq9apXZQ #caseswithcastle #melanoma #casestudy #riskstratification
-
-
NEW publication shows how diagnostic GEP testing can guide decisions for patient management including the extent of the surgical management and follow-up frequency. Melanocytic lesions with diagnostic and/or clinical ambiguity create challenges for dermatology providers to determine the most appropriate treatment plan. Read here: https://hubs.la/Q02v63yK0
A clinical impact study of dermatologists' use of diagnostic gene expression profile testing to guide patient management | Melanoma Management
futuremedicine.com